|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/19/21 4D Pharma plc 6-K 4/16/21 2:39K M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: 6-K Current, Quarterly or Annual Report by a Foreign HTML 12K
Issuer
2: EX-99.1 Miscellaneous Exhibit HTML 10K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of April 2021
Commission File Number: 001-40106
4D pharma plc
(Translation of Registrant’s name into English)
5th Floor, 9 Bond Court
Leeds
LS1 2JZ
United Kingdom
Tel: +44 (0) 113 895 013
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
C:
Announcement of Annual Report and Annual General Meeting
On April 15, 2021, 4D pharma plc (the “Company”) issued a press release to announce that the Annual Report for the year ended December 31, 2020 (the “Annual Report”) and the notice of the Company’s Annual General Meeting (“Notice of AGM”) have been posted to shareholders. The AGM will be held on Monday, May 24, 2021 at 10:00 am (British Summer Time) at the Company’s offices at 9 Bond Court, Leeds LS1 2JZ. Electronic copies of both the Annual Report and Notice of AGM can be found on the Company’s website at www.4dpharmaplc.com.
A copy of the press release is attached as Exhibit 99.1 to this current report on Form 6-K and is incorporated by reference herein.
C:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| 4D pharma plc | |
| Date: April 16, 2021 | /s/ Duncan Peyton |
| Duncan Peyton | |
| Chief Executive Officer |
C:
INDEX TO EXHIBITS
| Exhibit | ||
| Number | Exhibit Title | |
| 99.1 | Press Release, dated April 15, 2021. |
C:
| This ‘6-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 5/24/21 | EFFECT | |||
| Filed as of: | 4/19/21 | 6-K | ||
| Filed on / For Period end: | 4/16/21 | 6-K | ||
| 4/15/21 | ||||
| 12/31/20 | 20-F, 20-F/A | |||
| List all Filings | ||||